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The structure of proteins that are difficult to crystallize can often be solved by forming a noncovalent complex
with a helper protein—a crystallization ‘‘chaperone.’’ Although several such applications have been de-
scribed to date, their handling usually is still very laborious. A valuable addition to the present repertoire of
binding proteins is the recently developed designed ankyrin repeat protein (DARPin) technology. DARPins
are built based on the natural ankyrin repeat protein fold with randomized surface residue positions allowing
specific binding to virtually any target protein. The broad potential of these binding proteins for X-ray crys-
tallography is illustrated by five cocrystal structures that have been determined recently comprising target
proteins from distinct families, namely a sugar binding protein, two kinases, a caspase, and a membrane pro-
tein. This article reviews the opportunities of this technology for structural biology and the structural aspects
of the DARPin-protein complexes.Despite the continuous technical advances in protein crystallog-
raphy due to the worldwide effort in structural genomics pro-
grams that promote the application of automated procedures
in cloning, expression, purification, crystallization, data collec-
tion using synchrotron radiation, and computational crystallog-
raphy, the determination of some protein structures remains
a difficult task. Today, the main limitation is the growth of well-
diffracting crystals—a pure trial-and-error process—because
the formation of protein crystals depends on several unpredict-
able variables. In particular, advances in microscaling methodol-
ogy involving pipetting robots and automated imaging of individ-
ual experiments have allowed high throughput approaches
boosting the field. However, even with these advances, many
proteins resist forming suitable crystals on their own because
of inherent structural flexibility and instability. Consequently,
conformation stabilizing methods that help to crystallize proteins
seem attractive.
Approaches in this direction are removal or mutation of sur-
face residues known to be flexible (Lawson et al., 1991), the trim-
ming of the protein’s often flexible N- and C-terminal ends, or the
analysis of stable domains of larger multidomain proteins (Dere-
wenda, 2004). Another successful approach to promote the
crystallization of a particular protein has been the addition of
a conformation-stabilizing ligand. Current crystallization tools in-
clude the building of complexes with diverse known natural or
synthetic ligands, such as substrates, inhibitors, nucleic acid,
cofactors, or protein ligands. The benefits of such noncovalent
complexes can be manifold. A specific conformation of the tar-
get protein may be stabilized in such a complex. This increases
the chances to obtain crystals of proteins that otherwise adopt
several conformations and therefore resist forming crystals. In
addition, novel surfaces can potentially provide better crystal
contacts. Especially for membrane proteins, protein ligands
also increase the hydrophilic surface area of an otherwise small
non-transmembrane region. This strategy for the crystallization
of membrane proteins has repeatedly led to successful structure
determinations, as seen for many antibody fragment-membrane
protein complexes (Dutzler et al., 2003; Hunte et al., 2000; Iwata
et al., 1995; Zhou et al., 2001). Cocrystallization of a target pro-Structtein in complex with a proteinaceous ligand of known structure
potentially provides another advantage, namely the structure
solution by molecular replacement allowing to avoid the often
time-consuming determination of phases via heavy atoms as in
single/multiple anomalous dispersion or multiple isomorphous
replacement techniques.
DNA and RNA binding proteins are often cocrystallized with
their natural binding partner, fragments of DNA or RNA stabiliz-
ing the conformation of the protein (Anderson et al., 1984). In
many cases, however, the protein of interest lacks a natural bind-
ing partner, the natural binding partner might not be known, or it
might not be available for other reasons. Therefore, proteina-
ceous ligands, either natural or synthetic, have received a great
deal of attention in the field of structural biology. Antibody and
fragments thereof are the most successful molecules to be
used as high-affinity and specific binding proteins in biomedical
research and have not only been used as a binding protein but
also assist in crystallization (Amit et al., 1986). In 1995, Osterme-
ier et al. selected monoclonal antibodies for the first time against
a membrane protein, namely cytochrome c oxidase of Paracoc-
cus denitrificans, finally allowing the successful structure deter-
mination of the oxidase in complex with a FV fragment (Iwata
et al., 1995; Ostermeier et al., 1995). In addition to the well-
known Fab and Fv fragments, single-chain antibody domains
such as camelid VHH fragments or scFvs led to successful struc-
ture determinations (Desmyter et al., 1996; Kortt et al., 1994).
Recently, several studies using nonantibody scaffolds such as
affibodies (Hogbom et al., 2003; Wahlberg et al., 2003), mono-
bodies (Koide et al., 2007), and repeat proteins (Binz et al.,
2004) have shown that these molecules are potential alternatives
to antibody fragments in structural biology. These binding mole-
cules were developed as tools for basic research, but their po-
tential use in commercial applications (as specific reagents in
biomedical research and as potential therapeutic molecules)
was immediately apparent and quickly recognized (Gill and
Damle, 2006). Many novel binding proteins have improved on
the limitations of antibodies, in particular their rather low produc-
tion yield and intrinsic stability. Simultaneously, they retain the
beneficial properties of antibodies, namely specific and tighture 16, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1443
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ReviewFigure 1. Structure and Potential
Interaction Surface of a DARPin
(A) Ribbon representation of a designed ankyrin
repeat module. The side chains of the six random-
ized positions and the randomized framework res-
idue (position 26) are shown as yellow sticks, and
their positions within the 33-amino acid conserved
framework are labeled. Side chains of the con-
served residues are not shown for clarity.
(B) An N3C DARPin library member. The three re-
peat modules are colored purple; the capping re-
peats are colored blue. The randomized positions,
located mainly in the b turns and the first a helices
of the individual repeat modules, are shown as yel-
low sticks.
(C) Randomized potential interaction surface of an
N3C DARPin that normally provides the interaction
site (in yellow). The orientation is the same as in (B).
All figures were prepared with PyMol (DeLano,
2002).binding. Structural biologists likewise have a great interest in us-
ing these molecules as chaperones in crystallization.
In this review, we focus on one scaffold, the DARPins. The po-
tential of DARPins as promising compounds in drug discovery
and drug development has been reviewed recently (Stumpp
and Amstutz, 2007). We examine the five recently determined
X-ray structures of DARPin complexes and address several
questions concerning DARPin-target interactions. The diversity
of the successfully chosen antigens is paralleled by the diversity
of the interaction partners of natural ankyrin repeat proteins,
which indicates that the technology can be generally applied to
a very broad range of target molecules.
Drawbacks of Antibodies
The main advantage of antibodies is their ability to recognize
a wide range of target molecules with high affinity and specificity.
Besides proteins, antibodies can bind compounds such as pep-
tides, sugars and small molecules. However, natural antibodies
are complex multidomain molecules not well suited for cocrys-
tallization due to their flexible linker regions between domains
and their bivalent character. Therefore, only antibody fragments
have been applied for cocrystallization purposes. Fab or Fv frag-
ments contain the complete antigen recognition sites and are
therefore sufficient to retain the specific antibody-antigen inter-
action. Nevertheless, these fragments often derive from mono-
clonal antibodies, and their classical production by hybridoma
technology is time-consuming, expensive, and based on the
use of living organisms. The selection using recombinant and
synthetic libraries have facilitated their generation (Rothe et al.,
2008) and led to successful structure determinations (Fellouse
et al., 2007; Fellouse et al., 2005; Fellouse et al., 2004; Ye
et al., 2008) but the complicated multidomain molecular archi-
tecture with disulfide bonds still complicates their handling,
limits their use in reducing environments and requires special
production precautions in bacterial expression systems such
as expression in the periplasm to guarantee the correct disulfide1444 Structure 16, October 8, 2008 ª2008 Elsevier Ltd All rights resbond formation. This often affects the production yield since the
volume of the periplasm is limited. Despite these difficulties there
are numerous structures in complex with soluble target proteins
(Bentley, 1996) as well as more demanding membrane proteins
(Hunte and Michel, 2002) but the problems associated with all
antibody-derived crystallization chaperones inspire continu-
ously to search for alternative binding proteins with similar bind-
ing capabilities but superior properties regarding structure,
stability and throughput.
What Are DARPins?
DARPins are derived from the ankyrin repeat motif present in nu-
merous naturally occurring proteins. In nature, ankyrin repeat
containing proteins are involved in a wide variety of biological ac-
tivities and are present in all three superkingdoms (Bork, 1993).
Best documented is their involvement in specific protein-protein
interactions. The diversity of their roles in a cellular context is
further reflected in their localization, which can be the nucleus,
cytoplasm, and the extracellular space, where these proteins in-
teract with a large diversity of partners. The number of repeats
presented in a single ankyrin repeat protein and thus involved
in binding is highly variable so that ankyrin domains can bind
to host target molecules that vary considerably in size and
shape.
The 33-residue sequence motif of an ankyrin repeat forms
a well-defined architecture, consisting of a b turn, followed by
a pair of antiparallel a helices and a loop that builds the connec-
tion to the next repeat (Figure 1A). The characteristic secondary
structure components fold into an L-shaped conformation where
the helices form the stem and the loop projects outward at an an-
gle of about 90. Not uncommon are insertions between or within
repeats, mainly in the b turn/loop region (Sedgwick and Smer-
don, 1999). These insertions can be either a short helical seg-
ment or more complex motifs. The fully assembled ankyrin do-
main is elongated and slightly curved, manifested particularly
in high repeat number ankyrin repeat proteins (Figure 1B). Inerved
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the concave surface, formed by the b turn and the first a helix, is
commonly involved in binding the target molecules as shown by
the X-ray structures determined to date: p16INK4a-CDK6 (Russo
et al., 1998), p19INK4d-CDK6 (Brotherton et al., 1998; Russo
et al., 1998), GABPa-GABPb-DNA (Batchelor et al., 1998),
IkBa-NFkB (Huxford et al., 1998; Jacobs and Harrison, 1998;
Malek et al., 2003), p18INK4c-CDK6 (Jeffrey et al., 2000), CSL-
Notch-Mastermind (Wilson and Kovall, 2006), Nas6-Rpt3 (Naka-
mura et al., 2007b), and Gankyrin-S6 (Nakamura et al., 2007a).
Recently, Plu¨ckthun and coworkers have chosen the traits of
ankyrin repeat proteins for consensus-based protein library
design (Binz et al., 2003). Heeding the lessons of nature, they
created DNA libraries that encode DARPins consisting of differ-
ent numbers of repeat modules and special capping repeats
attached to the N and C termini of the protein (Figure 1B).
Therefore, the molecules are termed NxC, where x indicates
the number of ankyrin repeat modules. The consensus-designed
idealized repeat module consists of conserved residues essen-
tial for the formation and stabilization of the repeat module itself
and the interrepeat stacking interactions. These positions are
invariant and build the framework of the individual repeats. In
addition, positions not contributing to the structural integrity of
the basic fold were defined to be adaptive surface residues
(Figure 1A). These residues are positioned at the typical interface
region of the natural ankyrin repeat, namely the tip of the b turn
and along the exposed surface of the first a-helix (Figure 1C).
At these positions, the introduced diversification allows any
amino acid except proline and glycine (structurally unfavorable)
and cysteine (could form unwanted disulfide bonds). This
design resulted in a virtually unlimited repertoire of molecular
surfaces.
Selection Process
Rapid and easy production is a prerequisite for alternative scaf-
folds suitable for cocrystallization. Repeat protein libraries (Binz
et al., 2004; Binz et al., 2003) can be selected using powerful
library selection technologies such as ribosome display (RD)
(Hanes and Plu¨ckthun, 1997) or phage display (Smith, 1985), fi-
nally yielding specific binders to the target protein. RD is a com-
plete in vitro technology based on in vitro translation in which
noncovalent ternary complexes consisting of mRNA, ribosome,
and nascent protein chain are formed. These ternary complexes
can then be tested for binding to a particular target protein. This
system thereby guarantees the coupling of the genotype (mRNA)
to the phenotype (protein) and allows immediate access to the
genetic information of the binders. To achieve this, the coding
sequence of the protein is genetically fused to a C-terminal
spacer, allowing the correct folding of the nascent polypeptide
chain, and the construct lacks a Stop codon, thus preventing re-
lease of the mRNA and the polypeptide from the ribosome. Low
temperature and high concentrations of magnesium further sta-
bilize the ternary complexes. The disassembly of the complexes
results from depletion of magnesium, and the DNA is recovered
via reverse transcription. RD is particularly well suited for large
libraries, because no transformation steps limit the applicable
library size. Furthermore, as a cell-free system, it enables the
selection of cytotoxic proteins or of proteins with limited in vivo
stability.StructuAll the DARPin binders presented here were isolated from an
N3C library and were selected by RD. DARPin binders could
also be successfully selected from an N2C library, but these
did not yield crystals. Ankyrin repeat proteins consisting of four
to five repeats in total are very abundant in nature (Bork, 1993)
and also many of the solved natural ankyrin repeat structures
in complex with their target display such repeat numbers. The
target proteins chosen here were all recombinantly expressed,
purified, and either in vivo-biotinylated at a specific lysine in
the AviTag sequence (MBP, APH, and Caspase-2), in vitro-bioti-
nylated at diverse lysines on the surface (AcrB), or GST-tagged
(Plk-1) for immobilization. Within a few RD cycles (usually 3 to
4), it was possible to enrich the resulting residual library with pro-
teins that specifically and with high affinity bind to the target.
A subset of the DARPins obtained by RD was then tested indi-
vidually for binding using approaches suitable for the particular
target protein or the intended use of the binder. For MBP (Binz
et al., 2004) and Plk-1 (Bandeiras et al., 2008), a standard ELISA
was applied to identify a high-affinity binder. In the case of cas-
pase-2, an in vitro enzymatic activity test combined with a stan-
dard ELISA yielded an inhibitor (Schweizer et al., 2007). For APH
(Amstutz et al., 2005; Kohl et al., 2005) and AcrB (Sennhauser
et al., 2007), an in vivo assay was applied in which the inhibition
of the target protein through the DARPins resulted in hypersus-
ceptibility of the bacteria. Normally, the DNA of around 20
DARPins obtained from these assays was sequenced per target.
The pools often seemed already quite enriched, revealing groups
with similar sequences, although identical sequences were
rarely observed. Depending on the sequence variability, five to
ten complexes were then purified (yields between 50 and
200 mg/l), characterized, and subjected to crystallization.
Structures of DARPins in Complex with Different
Antigens
Maltose-Binding Protein: Proof of Principle
As a model protein for the approach of selecting a specific
DARPin protein by RD, the maltose binding protein from
Escherichia coli was chosen and represents the first successful
example for the selection and crystallization of a particular target
protein in complex with a DARPin. The structure of the complex
was determined at 2.3 A˚ resolution and the phases for this struc-
ture could be determined using a known structure of an unse-
lected DARPin previously solved (Kohl et al., 2003). This was
possible because the size of the DARPin (18 kDa) relative to
the size of maltose-binding protein (MBP) (43 kDa) was appro-
priate, and there was only one complex in the asymmetric unit.
Off7 binds the open form of MBP not involving the sugar-binding
cleft but binding three helices at one side of the elongated MBP
(Figure 2A). Four lysines forming a positive surface patch which
account for 60% of the buried surface area of MBP upon com-
plexation interact closely with off7 (Figure 3A).
This first structure showed that the interface between the se-
lected DARPin off7 and MBP indeed involves primarily residues
from all three randomized repeat modules, with the randomized
repeat module 2 contributing most to the binding (Figure 4A). The
two capping repeats are not involved in the interaction. The bind-
ing interface is comparable to the lower limit of natural protein-
protein interactions (Jones and Thornton, 1996) (Table 1) and is
formed by the concave surface of off7 and a convex surface ofre 16, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1445
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ReviewFigure 2. Open Book Illustrations of the Interaction Surfaces
of DARPins and their Respective Target Molecules
(A–D) Center: ribbon diagrams of the X-ray structures of the individual com-
plexes. Target proteins and DARPins are colored blue and purple, respec-
tively. Interfaces are highlighted in yellow. Left: the targets have been rotated
clockwise. Right: the DARPins have been rotated counterclockwise. Residues
that approach within 4 A˚ of the interaction partner are colored by element (C, N,
and O atoms are colored yellow, blue, and red, respectively).
(A) DARPin off7 in complex with MBP (PDB entry code 1svx).
(B) DARPin 3a in complex with APH (PDB entry code 2bkk).
(C) DARPin 3H10 in complex with Plk-1 (PDB entry code 2v5q).
(D) DARPin F8 in complex with caspase-2 (PDB entry code 2p2c). Caspase-2
is colored dark blue for the a subunits and light blue for the b subunits.
(E) DARPin 110819 in complex with AcrB (PDB entry code 2j8s). The AcrB sub-
units A, B, and C are colored dark blue, light blue, and gray, respectively. Left:
AcrB has been translated. Right: the DARPin has been rotated counterclock-
wise. Residues that approach within 4 A˚ of the DARPin are colored by element.1446 Structure 16, October 8, 2008 ª2008 Elsevier Ltd All rights reseMBP. It involves mainly amino acids at the randomized positions.
Off7 contains three framework mutations, of which one (H125Y)
is involved in MBP binding. The interface on the DARPin is further
characterized by seven aromatic residues, four of which are
tyrosines, which account for 72% of the buried surface area of
off7 upon complexation.
Aminoglycoside Phosphotransferase (30)-IIIa: The First
Inhibiting DARPin
The bacterial kinase aminoglycoside phosphotransferase (30)-
IIIa (APH) mediates antibiotic resistance to many pathogenic
bacteria and is structurally homologous to eukaryotic protein
kinases. A highly affine and potent intracellular kinase inhibitory
DARPin, named 3a, was selected (Amstutz et al., 2005), and the
structure of APH/3a with bound ADP was determined at a resolu-
tion of 2.15 A˚ with two heterodimeric complexes in the asymmet-
ric unit. The DARPin binds to two helical segments in the C-ter-
minal lobe of APH (Figures 2B and 3B).
On the DARPin surface, the interaction residues are located
mainly on the N-terminal capping repeat, on repeat modules
1 and 2, and, to a lesser extent, on module 3 (Figure 4A). As
for MBP/off7, there are no interactions involving the C-terminal
capping repeat, and as a consequence there was only weak den-
sity visible for this part of the molecule, indicating flexibility.
Whereas the structure of the DARPin is not affected by the
binding (Figure 4B), 3a binds to the two helices A and B in the
a-helical C-terminal lobe of APH, thereby stabilizing helix D in
a conformation unable to bind substrate (Figure 5A). In addition,
the aminoglycoside positioning loop connecting helices A and B
is disordered. Therefore, the structure of the C-terminal lobe of
the complex differs significantly from the structure of APH alone.
This affects in particular the C-terminal amino acid Phe264 of
helix D which is critically involved in substrate binding as re-
vealed by the kanamycin A bound APH structure (Hon et al.,
1997). In the DARPin complex, this interaction is distorted, and
thus the enzyme is unable to bind the antibiotic.
Polo-Like Kinase-1: An Arduously Crystallizable Target
The Ser/Thr protein kinase polo-like kinase-1 (Plk-1) is a key reg-
ulator of mitosis and is a well-validated drug target in cancer
therapy. Crystallization attempts for various constructs of the
wild-type kinase domain of Plk-1 using a multiparallel cloning
and expression approach have failed in the past. Therefore,
binders from a DARPin library selective for Plk-1 have been gen-
erated and have been used in cocrystallization trials. In this way,
the first structure of wild-type apo Plk-1 could be determined in
complex with the DARPin 3H10 at 2.3 A˚ resolution with two com-
plexes in the asymmetric unit. The DARPin binds to the C-termi-
nal lobe of the kinase directly below the ATP binding site
(Figure 2C). The binding epitope recognized by DARPin 3H10
is especially rich in Arg, Lys, and Glu residues (66% of the buried
surface area) enabling crystallization by masking a surface patch
of Plk-1 that is unfavorable for forming crystal contacts similar to
the surface residue mutation method (Figure 3C). Such residues
have high conformational freedom and are considered counter-
productive for crystal contact formation due to a loss of entropy
(Derewenda and Vekilov, 2006). As revealed by isothermal calo-
rimetry measurements, the overall interaction is endothermic
and apparently driven by entropy alone.
The three repeat modules are solely responsible for the inter-
action, and again there are mainly residues at the randomizedrved
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ReviewFigure 3. Comparison of the Epitopes on the
Different Target Molecules
Stereo view of the targets of the complexes. The mol-
ecules are shown in ribbon representation in the same
orientation as in the left panel of Figure 2. Interfacing
residues (4 A˚ distance cutoff) are shown as sticks





(E) Close-up view of AcrB.Structure 16, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1447
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ReviewFigure 4. Structural Differences between the Binding DARPins
(A) Contribution of each repeat to the buried surface area of the paratope.
(B) Structures of the DARPins bound to the diverse target molecules. The Ca atoms of the DARPins were least-squares superimposed using the program coot and
are shown in worm representation. The termini are labeled. The DARPins are colored as follows: red, unselected DARPin; orange, off7; yellow, 3a; green, 3H10;
cyan and light blue, F8 molecules P and Q; dark blue and gray, 110819 molecules D and E.
(C) Amino acid sequence alignment of the DARPins. Positions marked with X and Z in the consensus represent the randomized positions where in the case of X
any amino acid (except Cys, Gly, and Pro) or in the case of Z Asn, His, and Tyr is allowed. Residues marked in yellow and green indicate those involved in binding
of the target in the crystal structure (distance < 4 A˚; in green: accounts for more than 5% of the total buried surface area upon complex formation).positions involved (Figure 4A). The N-terminal capping repeat is
not involved in binding. Interestingly, the C-terminal capping re-
peat is fully disordered in the structure either due to the binding
of the kinase or due to clashings with the noncrystallographic
symmetry-related DARPin during crystal formation.1448 Structure 16, October 8, 2008 ª2008 Elsevier Ltd All rights reseCaspase-2: The First Specific Caspase-2 Inhibitor
Caspases are key molecules in the signaling of apoptosis and in-
flammation. The DARPin F8 was found to inhibit caspase-2 with
a subnanomolar inhibition constant. In addition, testing inhibition
against other caspases revealed that F8 was highly specificrved
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NHB NSBTarget DARPin Total Target DARPin Total Target DARPin
1svx
MBP-off7 (B-A)a 4.4 2.3 19 21 40 649 615 1264 4.2 8.1 8 2
2bkk
APH-3a (A-B) 1.7 2.15 21 27 48 925 850 1775 6.7 10.8 15 8
2v5q
Plk1-3H10 (A-D) 75 2.3 21 25 46 857 885 1742 6.0 14.3 14 9
2p2c
C2-F8 (BDA-P) 4.1 3.24 25 26 51 937 885 1822 12.1 10.2 8 9
C2-F8 (DBC-Q) 23 25 48 830 809 1639 10.5 9.7 6 9
2j8s
AcrB-110819 (BA-D) 28 2.54 35 33 68 1142 1186 2328 2.5 15.3 12 3
AcrB-110819 (AC-E) 32 31 63 969 1017 1986 2.2 13.4 11 2
Antibody-antigenc 777 ± 135 8.2 ± 0.7
Heterodimeric protein-
protein complexesc
983 ± 582 11.1 ± 2.7
Analyzed with the Protein Interfaces, Surfaces and Assemblies service PISA. The numbers may be at variance with those found by the original authors
owing to different programs used. Only the interface features of one complex are shown when there were several complexes in the asymmetric unit.
Nres – number of residues from the specified molecule that take part in the interface; NHB – number of potential hydrogen bonds across the interface;
NSB – number of potential salt bridges across the interface.
a Characters in parentheses show the chains participating in the interface as designated in the PDB file (target-DARPin).
b Affinities were determined by BIAcore technology. For Plk1-3H10 a KD measured by competition ELISA was described.
c According to Jones and Thornton (1996). The values for NHB were calculated from the tabulated hydrogen bonds/100 A˚
2 DASA.exclusively for caspase-2. The structure of the caspase-2/F8
complex at 3.24 A˚ resolution revealed the molecular basis for
the specificity as well as the allosteric mechanism of inhibition
which was also verified by kinetic analysis. The asymmetric
unit contained three caspase-2 dimers with two bound DARPins
each (Figure 2D). The main contact surface of caspase-2 is
formed by the 381 loop, involving diverse residues (Figure 3D).
Minor interactions involve the N-terminus of the other b-subunit
of the caspase. Regarding F8, all three repeat modules and one
framework residue in the N-terminal capping repeat are forming
the interface on F8 (Figure 4A).
The 381 loop forms one side of the active site cleft (Figure 5B).
The conformation of this loop is slightly shifted when comparedStructuwith the caspase-2/peptide inhibitor structure (Schweizer et al.,
2003), resulting in an opening of the active site cleft. Additional
rearrangements in the surrounding of the active site cleft and
the side chain of Tyr79 of F8 occupying partly the substrate sub-
pocket S5 of caspase-2 are the main reasons for the inhibitory
property of F8. The caspase-2/F8 complex shows that the allo-
steric inhibition of caspase-2 is extremely specific, which has
significant advantages over orthosteric ligands which often
lack specificity.
AcrB: The First Integral Membrane Protein in Complex
with a DARPin
The multidrug exporter AcrB, the inner membrane component of
the AcrAB-TolC drug efflux system in Escherichia coli is theFigure 5. Conformations of the Target
Molecules
(A) Close-up view of the superposition of the
DARPin binding region of APH in complex with
DARPin inhibitor 3a (blue and purple) and wtAPH
(gray). The APH/3a complex displays a distorted
drug binding site. The a helices A and B in the
C-terminal lobe of APH interacting with the DAR-
Pin are shifted, and the aminoglycoside position-
ing loop between these two helices is disordered.
This rearrangement leads to a 5- to 7-A˚ shift of
helix D with respect to wtAPH, which includes
the C-terminal residue Phe264. Kanamycin A
bound to wtAPH is shown in yellow, and hydrogen
bonds to the mainchain carboxyl group of Phe264
are indicated as dashed lines.
(B) Close-up view of the active-site cleft region of
caspase-2. Superimposed caspase-2 bound to Ac-LDESD-CHO (colored in gray and yellow) and to the DARPin F8 (colored in blue and red) is shown. In the
DARPin-bound form, the loop 381 and the C-terminal part of the a subunit (Ca), which includes the active site cysteine, are shifted with respect to the peptide
bound form.re 16, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1449
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this organism. This protein actively detoxifies the intracellular
space by exporting drugs to the cell exterior while importing pro-
tons. To explain the molecular mechanism of this process, the
availability of high-resolution structural information is a prerequi-
site. For this, and to show the applicability of the DARPin combi-
natorial libraries and of the ribosome display selection method to
membrane proteins, AcrB was chosen as model system. Al-
though AcrB can be crystallized on its own due to its large peri-
plasmic domain protruding from the lipid bilayer, the crystals of
the AcrB/110819 complex diffracted to 2.54 A˚ resolution, sub-
stantially better than all the previously published crystals of
AcrB alone (Murakami et al., 2002). In the structure, the DARPin
binds to the periplasmic part of AcrB and due to the distinctly dif-
ferent conformations of the subunits only two DARPins bind to
the trimeric protein (Figure 2E). The epitope on AcrB is mainly
formed by a b sheet connecting the pore domain with the TolC
docking domain, which are subdomains of the periplasmic por-
tion of the protein (Figure 3E). An additional interaction is formed
involving a helical segment and a b strand of the adjacent pre-
ceding subunit of AcrB via hydrophobic interactions and two hy-
drogen bonds.
All five repeats (including both capping repeats) of the DARPin
are involved in the interaction (Figure 4A). Comprising around
1100 A˚2 buried surface area on both the DARPin and AcrB,
and 68 residues in total, this complex showed the largest buried
surface area for a DARPin complex so far (Table 1).
Interestingly, the structure revealed a new conformation of the
molecule where the three subunits of AcrB were locked in differ-
ent conformations, revealing distinct channels in each subunit.
Furthermore, the structure indicated how in the protein the cou-
pling between the channel access, exit, and the putative proton
translocation site is achieved. It suggests a transport pathway
through the identified channels in the individual subunits by a ro-
tary mechanism. At the same time, this new conformation was
also observed without a bound DARPin by two individual groups
(Murakami et al., 2006; Seeger et al., 2006). In further studies,
DARPin 110819 also allowed the crystallization of otherwise un-
crystallizable mutants (K.M. Pos, unpublished data).
General Properties of DARPin-Target Interfaces
The structural properties forming the surface of the target pro-
teins recognized by DARPins vary from complex to complex
(Figure 2). A common trait between the different interfaces, how-
ever, is the overall curvature of the target protein interface area
enclosed by DARPins. This curvature is complementary to the
curvature of the randomized surface area of the DARPin. Fur-
thermore, all three internal randomized repeat modules are in-
volved in the interaction in all five complexes (Figure 4A). As
set out in the design, the predominant interaction is mediated
by residues in the randomized positions (Figure 4C); this is the
reason for the high specificity of the selected molecules. Inter-
estingly, the last residue of the individual repeat module, namely
randomized position 33, is not involved in any interface. In con-
trast, position 3 is heavily buried in most of the repeat modules.
In all complexes, framework residues also participate in the inter-
action with the target protein. In the case of the MBP and AcrB
binders, there is a mutated framework position H125Y and
D155N, respectively, contributing to the interaction. Such frame-1450 Structure 16, October 8, 2008 ª2008 Elsevier Ltd All rights reswork mutations can be explained as a result of the numerous
PCR cycles the DARPin-encoding DNA passes during the selec-
tion process.
The involvement of the capping repeats in the interface differs
greatly between the different complexes. Whereas the N-termi-
nal capping repeat is well ordered in all structures and involved
in binding in the APH, caspase-2, and AcrB complexes, the
C-terminal capping repeat is fully disordered in the Plk-1 com-
plex and partially disordered in the APH and caspase-2 complex.
It is solely involved in the interface of the AcrB/110819 complex,
where 7 residues of the C-terminal capping repeat are participat-
ing in the interface. In having the first interacting residue at posi-
tion 13 and the last at position 157, the full width of the 169 amino
acid residue DARPin is used in this complex. This provides the
most extensive interaction described to date.
The structures discussed here show that DARPins are not
restricted to recognize any specific amino acid sequence or
structure on the target. In all cases, the DARPins recognize na-
tive, nonlinear epitopes (Figure 3). There is no particular chemical
character found neither for the epitopes (target interface) nor for
the paratopes (DARPin interface). There are numerous aromatic
residues on the paratopes, but they seem to be less preferred
than in antibody paratopes (Padlan, 1990). An exception is the
MBP-off7 complex where the aromatic residues account for
72% of the buried surface area of the DARPin. The proportion
of aromatic residues in the epitopes is low, a fact that has
been observed in antibody-antigen interactions as well (Davies
and Cohen, 1996). Furthermore, charged residues seem to be
important for the interaction, accounting for nearly half of the
contact residues of the epitopes. Whereas all DARPins de-
scribed here are composed of five repeat modules, the total in-
terface sizes on the target molecules differ widely. The MBP/
off7 complex presents by far the smallest interface, comprising
40 residues and a combined buried surface area of only
1264 A˚2 (Table 1). In contrast, the largest interface observed in
the AcrB/110819 complex comprises 63 and 68 residues and
buries 1986 and 2328 A˚2 of the AcrB surface in the two interfaces
formed; all other complex interfaces are in between these values.
However, the interface sizes show great similarities to naturally
occurring ankyrin repeat protein, heterodimeric protein-protein,
and antibody-antigen complexes (Table 1).
Structural Rearrangements in the Target Proteins
and the DARPins
An often raised argument in the field of chaperone-assisted crys-
tallization is that binders might induce a conformational change
in the target molecules. Because the crystal structures of all tar-
get proteins chosen are also available without a binding partner,
it is possible to investigate conformational changes of the targets
on DARPin binding. The structures of MBP in the open confor-
mation without a ligand (PDB ID code: 1LLS [Rubin et al.,
2002]) and complexed MBP are very similar, with an overall Ca
rmsd below 1 A˚. Also, in the case of AcrB, the structures ob-
tained in 2006 (Murakami et al., 2006; Seeger et al., 2006) are re-
markably similar, considering the size of the protein (rmsd for
3110 Ca atoms 1 A˚). In addition, the observed asymmetry in
the crystal structure could also be detected in solution (Senn-
hauser et al., 2007). The overall structure of Plk-1 is also very
similar to two structures of a mutant solved at the same time,erved
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ReviewFigure 6. Diverse Crystal Contacts
Mediated by DARPins
(A) Crystal packing in the MBP-DARPin complex.
The crystals belong to space group P21. One com-
plex is shown in ribbon representation and colored
dark blue (MBP) and green (DARPin). The neigh-
boring molecules are shown in worm representa-
tion in light blue and purple. Crystal contacts are
mediated mainly between adjacent DARPin and
MBP molecules.
(B) Crystal contacts of AcrB molecules and DAR-
Pins. The crystals belong to space group
P212121. The AcrB subunits A, B, and C are col-
ored dark blue, light blue, and gray, respectively.
One of the two DARPins (in green) bound to the
periplasmic part of AcrB mediates essential crys-
tal contacts to the cytoplasmic part of a symme-
try-related trimer, resulting in a different packing
to AcrB crystallized without a DARPin.
(C) Asymmetric unit content of the Plk-1/DARPin
crystal. The two complexes are shown in ribbon
representation and are colored gray and blue
(Plk-1) and purple and green (DARPin). The
N- and C-terminal ends are labeled.each harboring a different ligand (Kothe et al., 2007), again indi-
cating that there is no binding protein induced conformational
change.
The interaction of the DARPin inhibitors with APH and cas-
pase-2 revealed conformations in which the target proteins
were inactive. This information is useful for finding novel ways
to inhibit the function of an enzyme. The structural rearrange-
ments there are quite considerable. In APH, helices A, B, and
D are significantly shifted with respect to kanamycin A-bound
APH (Hon et al., 1997), and the aminoglycoside positioning
loop connecting helices A and B is disordered (Figure 5A). In cas-
pase-2, the loops surrounding the active site cleft are altered
when compared with the caspase-2/peptide inhibitor structure
(Schweizer et al., 2003), resulting in an opening of the active
site cleft (Figure 5B). Nevertheless, we do not believe that these
structural rearrangements are caused by the DARPin, resulting in
an induced fit. Recalling the DARPin selection strategy, it is more
likely that the DARPins only bind to epitopes as presented by the
target proteins in a ‘‘lock and key’’-like fashion. In this way, the
selected DARPins can not only bind to proteins in their predom-
inant conformation but can also trap the proteins in conforma-
tions that are probably present in solution but are less populated,
thus inhibiting an enzyme in an allosteric way.
In all structures, the differences in the DARPin scaffold are
minimal upon binding and showed no essential rearrangements
of the global fold compared with an unselected DARPin alone
(Kohl et al., 2003) (Figure 4B). In agreement with the participation
of the individual repeats in the interaction, the strongest flexibility
can be observed in the C-terminal capping repeat. In the
DARPin-binding Plk-1, the C-terminal capping repeat cannot
even be localized in the crystal structure. The b turn regions of
the individual repeat modules also show some minor adapta-
tions when bound to a target protein.
DARPin-Mediated Crystal Contacts
The potential of DARPins to provide crystal contacts is best de-
scribed for the MBP/off7 and the AcrB/110819 complex. As
shown in Figure 6A, in the MBP/off7 complex the lattice interac-
tions involve only DARPin-DARPin and MBP-MBP contacts,Structuwhich occur within layers, and the direct binding interface be-
tween the two interaction partners is the sole contact form
between the layers.
In the crystal formed by the AcrB/110819 complex, crystal
contacts are mediated by the DARPin in such a way that, in ad-
dition to the interaction with the periplasmic domain of its target,
the convex side of the DARPin simultaneously forms crystal con-
tacts to the cytoplasmic polar surface of a symmetry-related
molecule of AcrB (Figure 6B). Because the crystal has the space
group P212121, this contact critically contributes to the stability
of the lattice (the mentioned contact occurs in all three dimen-
sions) and thus to the higher diffraction limits of the complex
crystal over the crystal formed by AcrB alone.
There are some proteins that could be crystallized only when
complexed to a cognate Fab fragment (Laver et al., 1990). A sim-
ilar case is Plk-1 that alone in its apo-form—a structure most
useful for drug design—did not crystallize. In complex with the
DARPin 3H10, however, Plk-1 did crystallize. Surprisingly, the
DARPin makes direct crystal contacts to the other DARPin in
the asymmetric unit via the third repeat module as the C-terminal
capping repeat is fully disordered (Figure 6C).
It is worth mentioning that cocrystallization with a DARPin
clearly was advantageous in the cases of AcrB and Plk-1,
whereas the opposite was true for caspase-2. Here, the diffrac-
tion quality of the DARPin complex was clearly worse (3.24 A˚)
than caspase-2 in complex with a peptide inhibitor (1.65 A˚)
(Schweizer et al., 2003). DARPins containing different numbers
of internal repeats might be selected to obtain better diffracting
crystals.
Conclusions
We have reviewed the recent results using DARPins as crystalli-
zation tools to crystallize difficult target proteins to understand
the natural and alternative conformations of these proteins.
DARPins are a class of designed binding molecules that repre-
sent a very promising alternative to antibodies. They retain the
affinity and specificity of antibodies but are far more stable,
and their simple architecture allows high-yield bacterial produc-
tion. Their use in biomedical and biotechnological research isre 16, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1451
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Reviewconsiderably more advantageous over antibodies. High-affinity
DARPins to a given target can rapidly be selected from very large
libraries within a few weeks. The use of in vitro selection systems
such as phage or ribosome display represents an advantage
over the traditional production of monoclonal antibodies in test
animals, as the binders are selected to a native protein under de-
fined buffer conditions. Therefore, the in vitro display techniques
guarantee that surface epitopes of the presented target protein
are selected. The use in structural biology is obvious from the
structures described here, and not only enables crystallization
of soluble and membrane proteins but also reveals conforma-
tions of the target proteins that otherwise are not detected
when inhibitors are selected. In the cases of DARPin inhibitors
of caspase-2 and APH, the crystals of the complex did not dif-
fract better; rather, the diffraction was worse than that of crystals
of the target proteins with small molecule compounds bound to
the active site. However, in both cases a conformation of the
target protein was revealed in which the protein is inactive.
This information is useful for finding new ways to modulate target
protein function.
To expand the applicability of the technology in protein
crystallography, heavy atom sites can be engineered into the
capping repeats. Crystals of target proteins with a heavy atom-
loaded DARPin is a great help in phasing using the single
anomalous dispersion method. This has already been success-
fully applied using a DARPin-MBP complex crystal (A. Plu¨ckthun
and M.G.Gru¨tter, unpublished data).
In conclusion, DARPins have the potential to (1) provide crys-
tals of a target protein that is difficult to crystallize, (2) provide
better diffracting crystals of the complex when the target protein
alone only poorly diffracts, (3) provide initial phases for molecular
replacement in cases where the DARPin and the target protein
are not too different in size, (4) provide phases by single anoma-
lous dispersion for complexes formed with heavy atom loaded
DARPins, and (5) reveal new insight into the function of a target
protein by stabilizing a conformation that in solution is less
populated.
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